Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

NCT01262391 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: Solifenacin succinate suspension 2.5 mg
DRUG: Solifenacin succinate suspension 5 mg
DRUG: Solifenacin succinate suspension 10 mg

Sponsor

Astellas Pharma Inc